Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (2): 292-293    DOI: 10.12892/ejgo3731.2018
Case Report Previous articles | Next articles
Dermatomyositis revealing a 18-year breast cancer recurrence
F. Lai-Tiong1, *()
1 Medical Oncology Unit Institut de Cancérologie du Gard; Rue du Professeur Henri Pujol, Nîmes, France
Download:  PDF(94KB)  ( 65 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Breast cancer is a well-known heterogeneous tumor, that includes inter- and intra-tumoral heterogeneity. These modifications in the phenotype can lead to modify the therapeutic strategy. The author reports the original case of a 66-year-old Caucasian woman, diagnosed with a breast cancer 18 years before. Initially it was a 32-mm, grade 2, ductal infiltrating breast carcinoma, negative for hormone receptors. The patient was treated with conservative surgery, and axillary dissection (eight positive nodes out of 21). Adjuvant chemotherapy and radiotherapy were delivered. Ten years later, the patient was diagnosed with pulmonary relapse. Biopsies were negative for hormone receptors and also for human epidermal growth factor 2 (Her2). The patient received chemotherapy. One year later, pleura effusion appeared. Biopsies of the pleura confirmed the metastasis of breast cancer, hormone receptors negative, but positive for Her2. She was then diagnosed with a paraneoplastic dermatomyositis. Eight lines of chemotherapy were given and currently the patient is continuing trastuzumab. That case illustrates the story of a very long-surviving breast cancer and its dedifferentiation. It underlies the necessity to realize new biopsies when the tumor relapses.
Key words:  Dermatomyositis      Her2 positive      Breast cancer      Paraneoplastic syndrome      Dedifferentiation      Cancer recurrence     
Published:  10 April 2018     
*Corresponding Author(s):  F. LAI-TIONG     E-mail:  florencelt@hotmail.fr

Cite this article: 

F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence. European Journal of Gynaecological Oncology, 2018, 39(2): 292-293.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3731.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I2/292

[1] Xiao-Peng Yu, Cai-Gang Liu, Fang Qiu, Fei Xing, Si-Jia Han, Ye Han, Gui-Jin He. Breast cancer overall-survival can be predicted with a 19 lncRNA tissue signature[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 838-843.
[2] Danping Qian, Yin Zhu, Le Xu, Tingting Dong, Ting Chen, Zhenghong Yu. Icariin induces apoptosis in breast cancer MCF-7 cells by regulating the MELK mediated PI3K/AKT signaling pathway[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 957-965.
[3] Maria Jesús Pla Farnós, Maria Eulalia Fernández-Montolí, Rosalía Pascal Capdevila, Amparo García Tejedor, Míriam Campos Delgado, Maite Bajen Lázaro, Anna Petit Montserrat, Raul Ortega Martínez, Evelyn Martínez Pérez, Sonia Pernas Simón, Jordi Ponce Sebastià. Role of sentinel node biopsy in breast cancer: a review[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 982-995.
[4] Ana Cristina Ruiz Peña, Yasmina José Gutiérrez, Javier Navarro Sierra, Andrea Espiau Romera, Pluvio Coronado Martín, Laura Baquedano Mainar. Health related quality of life scales in women diagnosed with gynecological and breast cancer: the role of resilience. A systematic review[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1048-1057.
[5] Englert-Golon Monika, Słopień Radosław, Smolarek Natalia, Burchardt Bartosz, Sajdak Stefan. Synchronous ovarian, endometrial and cervical cancer—case report[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1093-1094.
[6] Maria Szymankiewicz, Sebastian Szubert. Microbiological characteristics of early and late infectious complications following total pelvic exenteration due to cervical cancer recurrence—the significance of infections in long-term outcomes[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 742-751.
[7] Bartosz Kasprzak, Przemysław Zgórecki. Prophylactic mastectomy and ovariectomy—a religious perspective[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 414-417.
[8] Angelique Brands-Appeldoorn, Sabrina Maaskant-Braat, Loes Janssen, Vivianne Tjan-Heijnen, Rudi Roumen. Factors influencing cosmetic outcome of breast-conserving treatment in breast cancer: a narrative review[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 425-433.
[9] Chiara Cassani, Francesca Zanellini, Cristina Angela Camnasio, Diana Pettinato, Simona Secondino, Angelica Della Valle, Mario Urtis, Eloisa Arbustini, Silvia Martella, Arsenio Spinillo, Rossella Elena Nappi. Oral contraception use in BRCA gene mutation carriers: information for counselling in routine clinical practice[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 441-449.
[10] Ying Sun, Yi Jiang, Juveria Rahman, Xing Chen, Xiong Yuan, Jinhui Liu, Huihua Dai, Wenjun Cheng. Clinical characteristics and prognostic outcomes of gynaecological multiple primary malignant neoplasms[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 457-462.
[11] Maria Macciocca, Raffaella Fabbri, Roberto Paradisi, Lucia De Meis, Giacomo Caprara, Rossella Vicenti, Renato Seracchioli. In vitro study on the effect of double freezing on ovarian tissue preservation in cancer women[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 470-476.
[12] Shun-Li Zhang, Ya-Qi Wang, Jing-Hua Zhang, Ji-Wei Hu, Jie Ma, Zheng Gu, Yu Wang, Jing-Jing Chen. Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 530-536.
[13] Ping Yin, Zheng Wang, Yan Chen, Zhao-Quan Wen, Hong-Hai Hong, Yu-Ling Mao. Plasma concentration of piRNAs in breast cancer and its association with metastasis[J]. European Journal of Gynaecological Oncology, 2021, 42(2): 307-310.
[14] Rikiya Sano, Yoshiaki Ota, Soichiro Suzuki, Takuya Moriya, Mitsuru Shiota. Stage IA endometrial cancer recurrence around the ureter after laparoscopic surgery[J]. European Journal of Gynaecological Oncology, 2021, 42(2): 360-364.
[15] Rossella E. Nappi, Nicoletta Biglia, Ettore Cicinelli, Tiziana Di Paolantonio, Stefano Luisi, Massimo Stomati, Paola Villa, on behalf of the EVES study investigators. The European Vulvovaginal Epidemiological Survey (EVES) in Italy. Impact of vulvovaginal atrophy on the quality of life and sexual function in breast cancer survivors[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 38-44.
No Suggested Reading articles found!